NKGNW logo

NKGen Biotech Warrants (NKGNW) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

Indexes:

Not included

Description:

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California. NKGen Biotech, Inc. operates as a subsidiary of NKMAX Co., Ltd.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

N/A

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

No data about analysts updates

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Similar stocks

FAQ

  • What is the primary business of NKGen Biotech Warrants?
  • What is the ticker symbol for NKGen Biotech Warrants?
  • Does NKGen Biotech Warrants pay dividends?
  • What sector is NKGen Biotech Warrants in?
  • What industry is NKGen Biotech Warrants in?
  • What country is NKGen Biotech Warrants based in?
  • Is NKGen Biotech Warrants in the S&P 500?
  • Is NKGen Biotech Warrants in the NASDAQ 100?
  • Is NKGen Biotech Warrants in the Dow Jones?
  • When does NKGen Biotech Warrants report earnings?

What is the primary business of NKGen Biotech Warrants?

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California. NKGen Biotech, Inc. operates as a subsidiary of NKMAX Co., Ltd.

What is the ticker symbol for NKGen Biotech Warrants?

The ticker symbol for NKGen Biotech Warrants is NASDAQ:NKGNW

Does NKGen Biotech Warrants pay dividends?

No, NKGen Biotech Warrants does not pay dividends

What sector is NKGen Biotech Warrants in?

NKGen Biotech Warrants is in the Healthcare sector

What industry is NKGen Biotech Warrants in?

NKGen Biotech Warrants is in the Biotechnology industry

What country is NKGen Biotech Warrants based in?

NKGen Biotech Warrants is headquartered in United States

Is NKGen Biotech Warrants in the S&P 500?

No, NKGen Biotech Warrants is not included in the S&P 500 index

Is NKGen Biotech Warrants in the NASDAQ 100?

No, NKGen Biotech Warrants is not included in the NASDAQ 100 index

Is NKGen Biotech Warrants in the Dow Jones?

No, NKGen Biotech Warrants is not included in the Dow Jones index

When does NKGen Biotech Warrants report earnings?

The date for NKGen Biotech Warrants's next earnings report has not been announced yet